Immunotherapy in Recurrent Ovarian Cancer

Biomedicines, Journal Year: 2025, Volume and Issue: 13(1), P. 168 - 168

Published: Jan. 12, 2025

Background/Objectives: It remains challenging to treat recurrent ovarian cancer effectively as traditional interventions like chemotherapy and surgery have limited long-term efficacy, highlighting an urgent need for innovative approaches. Immunotherapy offers potential advantages in modulating the immune response against tumor cells has emerged a promising strategy management. This review discusses various immunotherapy modalities, including active passive strategies, cancer. Methods: We systematically reviewed recent advances cancer, efficacy mechanisms of single dual checkpoint inhibitors, inhibitor combinations with or radiotherapy, anti-angiogenic agents, PARP antibody–drug conjugates (ADC), vaccines, adoptive cell therapies (ACT). Additionally, we assessed emerging research on biomarkers predictive responsiveness Results: The findings indicate that immunotherapy, particularly involving inhibitors other demonstrates some showing enhanced benefits specific subtypes. microenvironment platinum-sensitive -resistant cases exhibits distinct immunological profiles, influencing therapy outcomes. Several been identified, potentially aiding patient stratification treatment optimization. Conclusions: significantly treatment, improving Further characteristics is crucial personalizing approaches enhancing their managing

Language: Английский

A noncanonical role of SAT1 enables anchorage independence and peritoneal metastasis in ovarian cancer

Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)

Published: April 3, 2025

Language: Английский

Editorial: Vital role of innate immunity in cancer immunotherapy

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: May 21, 2025

Language: Английский